Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
GlobalData on MSN21h
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
The Pharma Letter20h
Galderma wins EU twin approvals for Nemluvio
Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
PipelineReview.com21h
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Nemluviois the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...
Glamour on MSN12h
The Best Silk Sheets We Tested That Feel Great Against the Skin
Whether you’re hoping to keep your skin clearer or eliminate bedhead altogether, we’ve got great news: The best silk sheets ...
William Blair Predicts Incyte’s Q1 Earnings (NASDAQ:INCY)
Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for Incyte in a research note issued to investors on Monday, February 10th. William Blair analyst M.